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Background and aim 
Molecular imaging is a discipline in clinical healthcare and research that comprises 
a succession of procedures with the ultimate purpose of detecting, preferably at 
the earliest possible stage, molecular changes that can be associated with the 
genesis or progression of diseases (Figure 1). Specific pathological mechanisms can 
be unraveled and understood by targeting the appropriate biomarkers with an 
imaging agent, which enables to monitor the dynamics, localization, and expression 
of the target, and may enhance the development of more effective therapies. 
 
Figure 1. Key steps involved in the development of a molecular imaging study. 
General introduction  
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In addition to being decisive for the staging of several diseases, these minimally 
invasive molecular imaging techniques have also shown great potential to aid in 
drug development by assessing the pharmacokinetics and pharmacodynamics 
within living subjects in real-time, and are considered a key strategy towards 
personalized medicine [1]. Therefore, the quest for new biomarkers by which a 
particular pathological process can be identified, being indicators of disease 
progression and prognosis, is a continuously active field in medicinal chemistry [2]. 
Arginase, a vital enzyme of the urea cycle that catalyzes the hydrolysis of ʟ-arginine 
to ʟ-ornithine and urea, has been regarded as a potential biomarker of disease 
progression. With two isoforms widespread throughout the body, the action of 
arginase goes far beyond the boundaries of hepatic ureogenic function. The 
production of ʟ-ornithine, while competing with nitric oxide synthase (NOS) for the 
same physiological substrate (ʟ-arginine), can influence the endogenous levels of 
polyamines, proline, and NO•. Several pathophysiological processes may 
deregulate the subtle arginase/NOS balance, disturbing essential signaling 
pathways that maintain the homeostasis and functionality of the organism. Thus, 
an upregulated expression of arginase can be associated with several pathological 
processes that range from cardiovascular, immune-mediated, inflammatory, and 
tumorigenic conditions to neurodegenerative disorders [3]. 
Although it has long been known that arginase might be involved in pathological or 
counter-regulatory mechanisms of several diseases, it was only recently that this 
enzyme emerged as a potential therapeutic target, stimulating the development of 
highly potent arginase inhibitors [4]. As arginase is a potential biomarker of disease 
and a novel therapeutic target, it was hypothesized that these arginase inhibitors 
might have a second life outside pharmacological applications by being used as 
reference scaffolds to develop molecular imaging probes. These probes might aid 
in the early clinical detection of changes in arginase expression that are intrinsically 
related to poor prognosis and severity. Additionally, it was also proposed that the 
challenge of a real-time assessment, within living subjects, of the pharmacokinetic 
suitability and therapeutic efficacy of the arginase inhibitors can be facilitated by 
the use of molecular imaging. 
Another phenomenon that has attracted research interest, and whose mechanisms 
are still subject of discussion, is the potential therapeutic implication of 
statin-induced arginase/NOS signaling pathways, particularly the possibility of 
statins to influence the levels of polyamines or NO• [5]. These implications brought 
the perspective of the therapeutic use of statins in some of the most prevalent 
pathologies, such as cardiovascular disease [6], cancer [7], and especially 
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asthma [8]. Therefore, the development of a specific "toolbox" of molecular 
imaging probes that can be used to map arginase expression, and to assess 
statin-related mechanisms of action, might provide a basis to support the design of 
further research aiming to identify the spectrum of pleiotropic and off-target 
effects of statins, including possible interactions with ʟ-arginine metabolic 
pathways. 
 
Outline of the thesis 
Driven by the potential of arginase as a biomarker of disease progression, chapter 2 
reviews the pathophysiological role of this enzyme and brings a new perspective 
regarding the use of arginase inhibitors as scaffolds for the development of 
molecular imaging probes. Among molecular imaging modalities, positron emission 
tomography (PET) has an ideal combination of essential features, such as high 
detection and quantification sensitivity, penetration depth, and spatiotemporal 
resolution, being especially suitable for mapping subcellular processes in vivo [9]. 
The production of small molecules labeled with β+-emitting radionuclides to be 
used as PET imaging agents requires the establishment of reliable procedures, 
therefore recently developed and published late-stage labeling methods should be 
customized. Thus, chapter 3 describes a copper-mediated 18F-fluorodeboronation 
strategy suitable for the radiolabeling of non-activated (hetero)arenes [10]. This 
radiolabeling strategy was implemented for the first time in the radiochemistry 
laboratory of the Nuclear Medicine and Molecular Imaging (NGMB) department of 
the University Medical Center of Groningen (UMCG) by using, as a preliminary 
proof-of-concept test, several biorelevant arylboronic acid pinacol ester precursors 
synthesized via convergent multicomponent reactions (MCR). This optimized 
18F-fluorodeboronation strategy was then used to synthesize and evaluate the first 
radiolabeled arginase inhibitors reported in the literature. The results of these 
experiments, including the successful PET mapping of the arginase expression in 
preclinical models of allergic asthma and carcinoma, are described in chapter 4. 
Chapter 5 presents an overview of the potential impact of statins on ʟ-arginine 
metabolic pathways. Thus, to develop a potential molecular imaging tool for 
assessing statin-related mechanisms of action, a radiofluorinated analog of 
atorvastatin, one of the highest-selling clinically prescribed drugs and a potent 
fluorine-containing statin, was synthesized for the first time using different labeling 
strategies. 
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In chapter 6, the radiofluorination of atorvastatin was attempted via the 
copper-mediated 18F-fluorodeboronation strategy previously optimized and 
successfully applied to the radiolabeling of arginase inhibitors. However, the final 
yields achieved with this radiolabeling strategy were very modest and unreliable, 
not being compatible with further in vivo applications. 
To improve the synthesis of [18F]atorvastatin, another recently developed late-
stage radiofluorination strategy was attempted: the Ru-intermediated 
18F-deoxyfluorination of phenols. Due to its novelty and some practical drawbacks, 
this radiolabeling strategy still lacks multicenter assessments and was established 
for the first time in the radiochemistry laboratory of the NGMB department of the 
UMCG. Although the previous reports [11] had some practical disadvantages, which 
hindered broader applications, a newly enhanced, optimized, and easily automated 
approach is described in chapter 7. The successful and facilitated synthesis of 
[18F]atorvastatin enabled further evaluations in an atherosclerotic ex vivo model, 
and the pharmacokinetics of this radiotracer in healthy female and male rats is 
evaluated in chapter 8. 
Finally, chapter 9 summarizes the studies performed and describes future 
perspectives with concluding remarks. 
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